TY - JOUR
T1 - Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort
AU - Alijotas-Reig, Jaume
AU - Ferrer-Oliveras, Raquel
AU - Esteve-Valverde, Enrique
AU - Ruffatti, Amelia
AU - Tincani, Angela
AU - Lefkou, Elmina
AU - Bertero, Maria Tiziana
AU - Espinosa, Gerard
AU - Coloma, Emmanuel
AU - De Carolis, Sara
AU - Rovere-Querini, Patrizia
AU - Canti, Valentina
AU - Picardo, Elisa
AU - Fredi, Micaela
AU - Mekinian, Arsene
AU - Kuzenko, Anna
AU - Ruano, Anna
AU - Del Ross, Teresa
AU - Melnychuk, Taisiia
AU - Lundelin, Krista
AU - Llurba, Elisa
AU - Cervera, Ricard
AU - Toth, Bettina
AU - Saez-Comet, Luis
AU - Bremme, Katharina
AU - Mayer-Pickel, Karoline
AU - Gil-Aguado, Antonio
PY - 2016
Y1 - 2016
N2 - Aim: To analyse the prevalence and effects of inherited thrombophilic disorders (ITD) on maternal–foetal outcomes in cases of antiphospholipid antibody related to obstetric complications. Methods: Women with obstetric complaints who tested positive for aPL and with inherited thrombophilia were prospectively and retrospectively included. Results: ITD data were available in 208 of 338: 147 had obstetric antiphospholipid syndrome (OAPS) and 61 aPL-related obstetric morbidity (OMAPS). 24.1% had ITD. Laboratory categories I and IIa were more related to OAPS-ITD and IIb and IIc to OMAPS-ITD. No significant differences in obstetric complaints were observed. Regarding ITD carriers, treatment rates were higher in OAPS than in OMAPS for LMWH and LDA plus LMWH (P=.002). Conclusion: Cases with aPL-related OAPS/OMAPS showed no differences in maternal–foetal outcomes regardless of the presence of one ITD. Maternal thrombotic risk was low, with ITD-positive cases included. Registry data concur with Sydney criteria, whereby aPL-ITD-positive patients are classified as having antiphospholipid syndrome.
AB - Aim: To analyse the prevalence and effects of inherited thrombophilic disorders (ITD) on maternal–foetal outcomes in cases of antiphospholipid antibody related to obstetric complications. Methods: Women with obstetric complaints who tested positive for aPL and with inherited thrombophilia were prospectively and retrospectively included. Results: ITD data were available in 208 of 338: 147 had obstetric antiphospholipid syndrome (OAPS) and 61 aPL-related obstetric morbidity (OMAPS). 24.1% had ITD. Laboratory categories I and IIa were more related to OAPS-ITD and IIb and IIc to OMAPS-ITD. No significant differences in obstetric complaints were observed. Regarding ITD carriers, treatment rates were higher in OAPS than in OMAPS for LMWH and LDA plus LMWH (P=.002). Conclusion: Cases with aPL-related OAPS/OMAPS showed no differences in maternal–foetal outcomes regardless of the presence of one ITD. Maternal thrombotic risk was low, with ITD-positive cases included. Registry data concur with Sydney criteria, whereby aPL-ITD-positive patients are classified as having antiphospholipid syndrome.
KW - Immunology
KW - Immunology and Allergy
KW - Obstetrics and Gynecology
KW - Reproductive Medicine
KW - antiphospholipid antibody
KW - inherited thrombophilia
KW - obstetric outcome
KW - thrombosis
KW - treatment
KW - Immunology
KW - Immunology and Allergy
KW - Obstetrics and Gynecology
KW - Reproductive Medicine
KW - antiphospholipid antibody
KW - inherited thrombophilia
KW - obstetric outcome
KW - thrombosis
KW - treatment
UR - http://hdl.handle.net/10807/92980
UR - http://www.blackwellpublishing.com/journal.asp?ref=1046-7408&site=1
U2 - 10.1111/aji.12534
DO - 10.1111/aji.12534
M3 - Article
SN - 1046-7408
VL - 76
SP - 164
EP - 171
JO - American Journal of Reproductive Immunology
JF - American Journal of Reproductive Immunology
ER -